Mednet Logo

How would you treat Stage III unresectable adenocarcinoma of the lung with a BRAF-V600E mutation?

Is there any role for targeted therapy, or would you consider consolidation durvalumab for these patients?
2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Indiana University School of Medicine
Answered on

At this time, I do not think there is any role for BRAF directed therapy in patients with stage III unresectable adenocarcinoma. The standard of care remains chemoradiation followed by durvalumab. There is no evidence to support doing anything else. Unlike EGFR, for instance, where the use of consol...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Roswell Park Comprehensive Cancer Center
Answered on

At this time, I will still incorporate PACIFIC regimen in the treatment plan.

Join for free or sign in to see the full answer